Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys.

Johnson PR, Schnepp BC, Zhang J, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Clark KR.

Nat Med. 2009 Aug;15(8):901-6. doi: 10.1038/nm.1967. Epub 2009 May 17.

2.

Evolution of envelope-specific antibody responses in monkeys experimentally infected or immunized with simian immunodeficiency virus and its association with the development of protective immunity.

Cole KS, Rowles JL, Jagerski BA, Murphey-Corb M, Unangst T, Clements JE, Robinson J, Wyand MS, Desrosiers RC, Montelaro RC.

J Virol. 1997 Jul;71(7):5069-79.

3.

Vector-Mediated In Vivo Antibody Expression.

Schnepp BC, Johnson PR.

Microbiol Spectr. 2014 Aug;2(4):AID-0016-2014. doi: 10.1128/microbiolspec.AID-0016-2014. Review.

PMID:
26104192
4.

Limited impact of passive non-neutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques.

Nakane T, Nomura T, Shi S, Nakamura M, Naruse TK, Kimura A, Matano T, Yamamoto H.

PLoS One. 2013 Sep 9;8(9):e73453. doi: 10.1371/journal.pone.0073453. eCollection 2013.

6.

Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.

Liang X, Casimiro DR, Schleif WA, Wang F, Davies ME, Zhang ZQ, Fu TM, Finnefrock AC, Handt L, Citron MP, Heidecker G, Tang A, Chen M, Wilson KA, Gabryelski L, McElhaugh M, Carella A, Moyer C, Huang L, Vitelli S, Patel D, Lin J, Emini EA, Shiver JW.

J Virol. 2005 Oct;79(19):12321-31.

7.

Cross-protective immune responses induced in rhesus macaques by immunization with attenuated macrophage-tropic simian immunodeficiency virus.

Clements JE, Montelaro RC, Zink MC, Amedee AM, Miller S, Trichel AM, Jagerski B, Hauer D, Martin LN, Bohm RP, et al.

J Virol. 1995 May;69(5):2737-44.

8.

Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251.

Buge SL, Murty L, Arora K, Kalyanaraman VS, Markham PD, Richardson ES, Aldrich K, Patterson LJ, Miller CJ, Cheng SM, Robert-Guroff M.

J Virol. 1999 Sep;73(9):7430-40.

9.

Significant protection against high-dose simian immunodeficiency virus challenge conferred by a new prime-boost vaccine regimen.

Schell JB, Rose NF, Bahl K, Diller K, Buonocore L, Hunter M, Marx PA, Gambhira R, Tang H, Montefiori DC, Johnson WE, Rose JK.

J Virol. 2011 Jun;85(12):5764-72. doi: 10.1128/JVI.00342-11. Epub 2011 Apr 13.

10.

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.

Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, Huang L, Harris VA, Long RS, Liang X, Handt L, Schleif WA, Zhu L, Freed DC, Persaud NV, Guan L, Punt KS, Tang A, Chen M, Wilson KA, Collins KB, Heidecker GJ, Fernandez VR, Perry HC, Joyce JG, Grimm KM, Cook JC, Keller PM, Kresock DS, Mach H, Troutman RD, Isopi LA, Williams DM, Xu Z, Bohannon KE, Volkin DB, Montefiori DC, Miura A, Krivulka GR, Lifton MA, Kuroda MJ, Schmitz JE, Letvin NL, Caulfield MJ, Bett AJ, Youil R, Kaslow DC, Emini EA.

Nature. 2002 Jan 17;415(6869):331-5.

PMID:
11797011
11.

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV.

Ourmanov I, Brown CR, Moss B, Carroll M, Wyatt L, Pletneva L, Goldstein S, Venzon D, Hirsch VM.

J Virol. 2000 Mar;74(6):2740-51.

12.

ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge.

Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M Jr, Carville A, Mansfield KG, Lifson JD, Li W, Desrosiers RC, Johnson RP, Evans DT.

PLoS Pathog. 2012;8(8):e1002890. doi: 10.1371/journal.ppat.1002890. Epub 2012 Aug 23.

13.

Effect of therapeutic immunization using Ad5/35 and MVA vectors on SIV infection of rhesus monkeys undergoing antiretroviral therapy.

Shimada M, Wang HB, Kondo A, Xu XP, Yoshida A, Shinoda K, Ura T, Mizuguchi H, Klinman D, Luo JL, Bai H, Okuda K.

Gene Ther. 2009 Feb;16(2):218-28. doi: 10.1038/gt.2008.152. Epub 2008 Oct 16.

PMID:
18923453
14.

Protection against lethal simian immunodeficiency virus SIVsmmPBj14 disease by a recombinant Semliki Forest virus gp160 vaccine and by a gp120 subunit vaccine.

Mossman SP, Bex F, Berglund P, Arthos J, O'Neil SP, Riley D, Maul DH, Bruck C, Momin P, Burny A, Fultz PN, Mullins JI, Liljeström P, Hoover EA.

J Virol. 1996 Mar;70(3):1953-60.

15.

Role of complement and antibodies in controlling infection with pathogenic simian immunodeficiency virus (SIV) in macaques vaccinated with replication-deficient viral vectors.

Falkensammer B, Rubner B, Hiltgartner A, Wilflingseder D, Stahl Hennig C, Kuate S, Uberla K, Norley S, Strasak A, Racz P, Stoiber H.

Retrovirology. 2009 Jun 21;6:60. doi: 10.1186/1742-4690-6-60.

16.

A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge.

Patterson LJ, Robey F, Muck A, Van Remoortere K, Aldrich K, Richardson E, Alvord WG, Markham PD, Cranage M, Robert-Guroff M.

AIDS Res Hum Retroviruses. 2001 Jun 10;17(9):837-49.

PMID:
11429125
17.

Towards a genetic AIDS vaccine.

Bordería AV, Berkhout B.

Retrovirology. 2009 Oct 16;6:93. doi: 10.1186/1742-4690-6-93.

18.
19.

Reduction of viral loads by multigenic DNA priming and adenovirus boosting in the SIVmac-macaque model.

Suh YS, Park KS, Sauermann U, Franz M, Norley S, Wilfingseder D, Stoiber H, Fagrouch Z, Heeney J, Hunsmann G, Stahl-Hennig C, Sung YC.

Vaccine. 2006 Mar 10;24(11):1811-20. Epub 2005 Oct 25.

PMID:
16274888
20.

Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, DeSilva V, Fritts L, Bett AJ, Casimiro DR, Shiver JW, Robert-Guroff M, Robertson MN, McChesney MB, Gilbert PB, Miller CJ.

J Virol. 2012 Feb;86(4):2239-50. doi: 10.1128/JVI.06175-11. Epub 2011 Dec 7.

Supplemental Content

Support Center